Clinical trials: Resistance, Disease
Type 2 Diabetes Mellitus
Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin
In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.
- Trial name
- NCT00213122
- Testing
- miglitol
- Where
- Japan
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Prostatic Neoplasms, Castration-Resistant
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine…
- Trial name
- NCT02803437
- Testing
- Radium-223 dichloride (Xofigo, BAY 88-8223)
- Where
- Japan
- Volunteers
- 334 people
- Sponsor
- Bayer
Herpes Simplex, HIV Infections
An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies
To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients.
- Trial name
- NCT00002272
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
Seizures
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric participants with treatment-resistant seizure disorders, including…
- Trial name
- NCT02318602
- Testing
- Cannabidiol Oral Solution
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- INSYS Therapeutics Inc
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Ovarian Neoplasms
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
The primary purpose is to assess the safety and tolerability of tilvestamab following IV administration of multiple doses to participants with HGSOC who have been treated with at least 1 complete course of platinum-based…
- Trial name
- NCT04893551
- Testing
- Tilvestamab
- Where
- 9 sites in Norway, Singapore and 2 more
- Volunteers
- 16 people
- Sponsor
- BerGenBio ASA
Atherosclerosis, Diabetes Mellitus
TART - Troglitazone Atherosclerosis Regression Trial
The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
- Trial name
- NCT00116545
- Testing
- troglitazone
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Parke-Davis
Pneumonia
Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days
A multinational, multicenter, randomized, double-blind, study in areas of high pneumococcal resistance comparing the clinical efficacy and health outcomes of outpatients with mild to moderate Community-Acquired Pneumonia (CAP)…
- Trial name
- COBRA II (NCT00237445)
- Testing
- telithromycin, azithromycin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Sanofi
Colorectal Neoplasms
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC)…
- Trial name
- NCT04515394
- Testing
- Tepotinib, Cetuximab
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Ovarian Cancer, Fallopian Tube Cancer
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
This is a Phase 3, randomized, open-label, 2-stage, multicenter study of navicixizumab with or without paclitaxel compared with paclitaxel monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer and…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT05043402
- Testing
- navicixizumab, Xerna™ TME Panel
- Volunteers
- 400 people
- Sponsor
- OncXerna Theraputics, Inc.
Hypertension
A Multicenter Study to Evaluate the ROX Anastomotic Coupler System (ACS) In Patients With Severe Hypertension
The purpose of this study is to evaluate the safety and performance of the ROX Anastomotic Coupler System (ACS) in patients with severe hypertension.
- Trial name
- NCT01682057
- Testing
- ROX ANASTOMOTIC COUPLER SYSTEM (ACS)
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- ROX Medical, Inc.
Metabolic Syndrome, Type 2 Diabetes
LUPS-Lipids and Glucose Under Prospective Surveillance
Prospective, non-randomized cohort study to analyse genetic variations, dietary patterns, perceived stress and anxiety and early changes in lipid metabolism leading to the metabolic syndrome and type 2 diabetes
- Trial name
- LUPS (NCT01313156)
- Where
- 2 sites in Germany
- Volunteers
- 1,962 people, healthy volunteers welcome
- Sponsor
- Asklepios proresearch
Prostate Cancer
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear Export (SINE) selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- SHIP (NCT02146833)
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Karyopharm Therapeutics Inc
Metabolic Syndrome
VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt
Primary objective: To assess the effect of rimonabant on visceral fat area over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with metabolic syndrome Secondary objectives: To…
- Trial name
- VICTORIA (NCT00299325)
- Testing
- Rimonabant, Mild hypocaloric diet
- Where
- 9 sites in United States, Canada and 7 more
- Volunteers
- 254 people
- Sponsor
- Sanofi
Metastatic Castration-resistant Prostate Cancer
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
An open-label, multi-center, Phase 1/2 study to determine the safety, tolerability, and feasibility of dosing adult patients with mCRPC with genetically modified autologous T-cells (TmPSMA-02) engineered to express a CAR capable…
- Trial name
- NCT05489991
- Testing
- TmPSMA-02
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tceleron Therapeutics, Inc.
Prostate Cancer
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
The study will be conducted in 2 Stages. The primary objective of Stage 1 of the study is to identify the maximum tolerated dose (MTD) of ES414 administered intravenously to patients with mCRPC.
- Trial name
- NCT02262910
- Testing
- ES414
- Where
- 7 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Aptevo Therapeutics
Type 2 Diabetes Mellitus (T2DM)
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin.
- Trial name
- CONTROL (NCT07057479)
- Testing
- Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Prostate Cancer
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
The purpose of the study is to determine the safety and clinical benefit of the combinations of abiraterone acetate and prednisone or abiraterone and dexamethasone in prostate cancer patients.
- Trial name
- NCT01867710
- Testing
- Abiraterone Acetate, Prednisone 5 mg twice daily, Prednisone 5 mg once daily
- Where
- 17 sites in Belgium, Germany and 2 more
- Volunteers
- 164 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Prostate Cancer Metastatic
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
This first-in-human, Phase 1/2, open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of JSB462 (luxdegalutamide, previously ARV-766) administered as monotherapy and in…
- Trial name
- NCT05067140
- Testing
- ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone)
- Where
- 17 sites in United States
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Neoplasms, Genital Neoplasms, Male
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Trial name
- NCT01217697
- Testing
- Abiraterone Acetate, Prednisone\Prednisolone
- Where
- 297 sites in United States, Australia and 22 more
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.